| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| CAR-T |
0 |
0.78 |
| Leukemia |
0 |
0.7 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.52 |
| Lymphoma |
0 |
0.43 |
| B-Cell Lymphoma |
0 |
0.39 |
| Cancer |
0 |
0.3 |
| Targeted Cancer Therapy |
0 |
0.28 |
| Toxicology |
0 |
0.21 |
| Tyrosine Kinase Inhibitor |
0 |
0.17 |
| Multiple Myeloma |
0 |
0.16 |
| Tyrosine Kinase |
0 |
0.15 |
| Stem Cell Research and Therapy |
0 |
0.14 |
| Blood |
0 |
0.12 |
| Antigens |
0 |
0.09 |
| Cell Transplantation |
0 |
0.07 |
| Adverse Effects |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Ohio |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Transplantation |
0 |
0.06 |